Linezolid-induced Pancytopenia

Overview

Journal BMJ Case Rep

Specialty General Medicine

Date 2018 Jul 29

PMID 30054325

Citations 2

Authors

Ross Leader

James Hackett

Anne Allan

Paul Carter

Affiliations

Soon will be listed here.

Abstract

Linezolid is a bacteriostatic antibiotic of the Oxazolidinone class; it works by inhibiting the initiation of protein synthesis on bacterial ribosomes. Due to its excellent bioavailability after oral dosing, it has become an important tool in combating multi-drug-resistant bacteria including glycopeptide-resistant enterococci and methicillin-resistant Side effects are multiple and potentially serious. We report the case of an 87-year-old man who developed pancytopenia secondary to a 6-week course of linezolid. Withdrawal of the antibiotic was decided as the treatment and resolution of the pancytopenia was evident within 2 weeks. Clinicians should be aware of this side effect of linezolid therapy and that weekly full blood count monitoring is paramount.

Citing Articles

Linezolid-Induced Pancytopenia in Patients Using Dapagliflozin: A Case Series.

Li M, Shen W, Li Y, Teng J Infect Drug Resist. 2022; 15:5509-5517.

PMID: 36158232 PMC: 9505346. DOI: 10.2147/IDR.S375694.

Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients.

Oehadian A, Santoso P, Menzies D, Ruslami R IDCases. 2022; 29:e01591.

PMID: 35957807 PMC: 9358446. DOI: 10.1016/j.idcr.2022.e01591.

References

Nagiec E, Wu L, Swaney S, Chosay J, Ross D, Brieland J . Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob Agents Chemother. 2005; 49(9):3896-902. PMC: 1195406. DOI: 10.1128/AAC.49.9.3896-3902.2005. View

Mendes R, Deshpande L, Jones R . Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. Drug Resist Updat. 2014; 17(1-2):1-12. DOI: 10.1016/j.drup.2014.04.002. View

Lakhani N, Thompson W, Bombassaro A . Probable linezolid-induced pancytopenia. Can J Infect Dis Med Microbiol. 2007; 16(5):286-8. PMC: 2095045. DOI: 10.1155/2005/961613. View

Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Kobayashi T, Sadoh S . Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother. 2010; 17(1):70-5. DOI: 10.1007/s10156-010-0080-6. View

Birmingham M, Rayner C, Meagher A, Flavin S, Batts D, Schentag J . Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003; 36(2):159-68. DOI: 10.1086/345744. View

Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y . Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents. 2010; 36(2):179-81. DOI: 10.1016/j.ijantimicag.2010.02.019. View

Brier M, Stalker D, Aronoff G, Batts D, Ryan K, OGrady M . Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother. 2003; 47(9):2775-80. PMC: 182634. DOI: 10.1128/AAC.47.9.2775-2780.2003. View

Kuter D, Tillotson G . Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy. 2001; 21(8):1010-3. DOI: 10.1592/phco.21.11.1010.34517. View

Hiraki Y, Tsuji Y, Hiraike M, Misumi N, Matsumoto K, Morita K . Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis. 2011; 44(1):60-4. DOI: 10.3109/00365548.2011.608712. View

10.

Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M . Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012; 67(8):2034-42. DOI: 10.1093/jac/dks153. View

11.

Leach K, Swaney S, Colca J, McDonald W, Blinn J, Thomasco L . The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell. 2007; 26(3):393-402. DOI: 10.1016/j.molcel.2007.04.005. View

12.

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

13.

Gerson S, Kaplan S, Bruss J, Le V, Arellano F, Hafkin B . Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002; 46(8):2723-6. PMC: 127358. DOI: 10.1128/AAC.46.8.2723-2726.2002. View